IBIO · iBio, Inc.
$1.40
+0.02 (+1.45%)
At close · Jul 23
Going-concern doubt
— cleared May 12, 2026
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Market Cap
$69.55M
Shares
49.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.40
Open$1.35
Day$1.33–1.41
52W$0.56–3.82
Avg vol 30d951K
Short int4.7M · 9.4% float · 5.1d
Short vol40%
Last earningsSep 27, 2022
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
−14%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
26%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−35%
trailing
YTD return
−27%
this year
Relative strength
−42%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
5 of 52 funds reported for Jun 30 · net -20.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.45% of float · ▲ +25.0% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
52 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+73%
Y/Y
Free cash flow
$-15.3M
Balance sheet
$8.6M
net cash
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
7.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
26%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
5 of 52 funds reported for Jun 30 · net -20.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.45% of float · ▲ +25.0% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
52 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 26%
52-wk high $4
vs 200-day avg -22%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBIO
this stock
iBio, Inc.
|
$69.55M | -27.5% | -20.5% | — | 9.4% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$57.84B | +9.9% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBIO | +3.7% | -13.6% | -34.9% | -20.0% | -27.5% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | +4.7% | -15.5% | -42.4% | -20.1% | -37.1% |